Recombinant Human VEGFR2/Flk-1/KDR Protein (His &GST Tag)(Active)
Size: 50μg
Catalogue Number: PKSH030427-50
Citations, Manuals and MSDS Available upon request.
Abbreviation: VEGFR2; Flk-1; KDR
Target Symptom: Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; CD309; Flk-1; FLK1; VEGFR; VEGFR2
Research Area: Signal Transduction; Microbiology; Cardiovascular; Cancer; metabolism; Stem cells
Target Species: Human
Expression Host: Baculovirus-Insect Cells
Application: Enzyme
Fusion Tag: N-His-GST
Accession: NP_002244
Background: VEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as a major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.
Activity: The specific activity was determined to be 10 nmol/min/mg using Poly(Glu, Tyr) 4:1 as substrate.
Sequence: Asp807-Val1356
Purity: > 78 % as determined by reducing SDS-PAGE.
Formulation: Supplied as sterile solution of 50mM Tris, 100mM NaCl, pH 8.0, 10% glycerol, 2mM GSH
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution: Not Applicable
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Calculated MW: 89.3 kDa
Observed MW: 110 kDa
Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.
Research Use Only